Evercore ISI downgraded Carlyle to In Line from Outperform with an unchanged price target of $32. The analyst cites valuation for the downgrade after the 25% move up in the stock in November and its addition to the S&P MidCap 400 Index. Carlyle continues to be more private equity centric than most, “where the healing is slow” and capital raising is challenging, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CG:
- Here’s Why Carlyle Group Stock (NASDAQ:CG) Jumped Yesterday
- Carlyle to replace ICU Medical in S&P 400 at open on 11/30
- McDonald’s to acquire Carlyle’s stake in McDonald’s China
- Carlyle price target raised to $40 from $38 at BMO Capital
- Carlyle price target lowered to $38 from $39 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com